Raise by Fusion42
Fusion42 Scout Wire
Capital Reports
Who's InvestingWeekly · Mon 08:00 UTCCapital UnlockedBi-weekly · Wed 08:00 UTC
Benchmarks
Benchmarks HomeFundsRoundsSectors
AI VC IndexCapital FlowAbout

Switch product

Fusion42RaiseScoutWire

Capital Reports

All editionsWho's InvestingWeekly · Mon 08:00 UTCCapital UnlockedBi-weekly · Wed 08:00 UTC

Database & benchmarks

Benchmarks HomeFundsRoundsSectorsStagesAI VC IndexCapital Flow Index

Account

Sign in
← Back

Medicxi V

vc$584.1MCo-investsLeads rounds

◆ Fund Size

$584.1M

◆ Check Size

$1.0M→$20.0M

◆ Location

United Kingdom

◆ Activity

Statusactively investing

◆ Links

Website ↗@Medicxi on X ↗

◆ Share this fund

ShareXLinkedInEmail

◆ Investment Thesis

Support companies with clear product visions to transform patient care, focusing on asset-focused biotechs across all stages of development via a capital-efficient investment strategy.

◆ About Medicxi

Medicxi is a leading European life sciences venture capital firm that employs a pioneering asset-centric investment model, creating and backing biotechnology companies focused on developing transformative therapies for patients. Medicxi V, a €500 million ($581 million) oversubscribed fund closed in November 2025, continues this strategy by supporting drug hunters and entrepreneurs in building asset-focused biotechs while also investing in existing companies at all development stages. The firm drives financial and intellectual resources toward single assets with clear product visions to maximize value creation.

◆ Sectors

BiotechDrug DiscoveryMedtech

◆ Stages

growthpre-seedseedseries-aseries-bseries-c

◆ Geography Focus

Europe

◆ Team

NameTitleRoleLinks
David GraingerCo-founder and Venture PartnerVenture Partnerin𝕏
Francesco De RubertisCo-founder and PartnerPartnerin𝕏
Francois PrinslooAssociateAssociate
Freya Svedberg-KeatingAssociateAssociate
Giovanni MariggiCo-founder and PartnerPartnerin𝕏
Giovanni PericoliniCo-founder and PartnerPartnerin
Giuseppe ZoccoCo-Founder and Partner—
Moncef SlaouiVenture PartnerVenture Partner
Nick WilliamsPartnerPartner
Richard LeeCo-founder and Operating PartnerOperating Partnerin
Shyam M.Partner—
Shyam MasraniPartnerPartner
Thibaut De SmedtVenture PartnerVenture Partner
Victoria TaylorPrincipalPrincipal

◆ Notable Investments

LeviceptViceBio (acquired by Sanofi for $1.6 billion)Vaderis TherapeuticsEthyreal BioCurevo (acquired by Lilly)Centessa Pharmaceuticals (acquired by Lilly)RAPT Therapeutics (acquired by GSK)CellZome (acquired by GlaxoSmithKline)GenMabGenSight BiologicsMicromet (acquired by Amgen)VaxcyteMolecular PartnersPanGenetics (acquired by Abbott)Parallele Biosciences (acquired by Affymetrix)Profibrix (acquired by The Medicines Company)VersartisKaerus Biosciences (acquired by Servier)Phathom PharmaceuticalsMiroBio (acquired by Gilead Sciences)

◆ Traits

Leads rounds

Co-invests

◆ FAQ

What does Medicxi V invest in?

Medicxi V invests in Biotech, Drug Discovery and Medtech at the growth, pre-seed, seed, series-a, series-b and series-c stages.

Which geographies does Medicxi V focus on?

Medicxi V focuses on Europe, and is headquartered in United Kingdom.

What is Medicxi V's typical check size?

Medicxi V typically writes checks of $1M to $20M.